Durect — Technical Presentation (November 2023)
15 slides from Durect's technical presentation, Nov 7, 2023
Slide 1: Phase 2b AHFIRM Topline Results
Phase 2b AHFIRM Topline Results November 2023 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulations, which are subject
Slide 3: Key Takeaways from Phase 2b AHFIRM Trial
Strong rationale for advancing to a registrational Phase 3 trial with 90-day mortality as the primary endpoint Key Takeaways from Phase 2b AHFIRM Trial Compelling signal in the key secondary endpoint of mortality reduction at 90 days 41% reduction with 30 mg dose 35% reduction with 90 mg dose Numeri
Slide 4: What is Alcohol-associated Hepatitis?
Reference: 1 Hughes E, Hopkins LJ, Parker R. 2018. PLOS ONE, 13(2): e0192393 What is Alcohol-associated Hepatitis? Life-threatening form of alcohol-associated liver disease (ALD) Up to 30% of patients die within 90 days1 Characterized by jaundice and severe inflammation – indicative of SIRS (Systemi
Slide 5: Market Opportunity Supports >$1 Billion Peak Sales
Market Opportunity Supports >$1 Billion Peak Sales ~158,000 U.S. hospitalizations in 20201 Incidence may yield ~300K hospitalizations by 20342 based on historical rapid yearly growth rate of 5.5% between 2015-20193 86% of hospitalized AH patients are insured3 Each hospitalization episode with AH1: D
Slide 6: Phase 2b AHFIRM Trial Design
Phase 2b AHFIRM Trial Design Study Design Screening Period 30 mg larsucosterol 90 mg larsucosterol Standard of Care (SOC)2 Severe AH patients with MDF1 score ≥ 32 and MELD1 score 21-30 307 subjects randomized to three groups in a 1:1:1 ratio Global trial conducted in U.S., E.U., Australia and U.K. D
Slide 7: Median Baseline Characteristics and Trial Outcome by Arm
Median Baseline Characteristics and Trial Outcome by Arm 1 Based on central lab MELD score SOC Larsucosterol 30 mg Larsucosterol 90 mg Number of patients randomized 103 102 102 Number of patients with 90-day outcome data 102 99 101 MELD1 25.0 24.0 25.0 MDF 61.50 57.20 63.00 Age 47.0 44.0 43.0 Deaths
Slide 8: Numerical Improvement in Primary Endpoint
Numerical Improvement in Primary Endpoint Did not achieve statistical significance p = 0.533 p = 0.196 Primary endpoint was analyzed using a hierarchical assessment of patient outcomes to calculate a win probability for each of the 30 mg and 90 mg dose of larsucosterol compared with standard of care
Slide 9: Clinically Meaningful Trend Toward Reduced Mortality
Clinically Meaningful Trend Toward Reduced Mortality p = 0.126 p = 0.070 -41% -35%
Slide 10: Kaplan-Meier Analysis of Mortality
Kaplan-Meier Analysis of Mortality p-value = 0.057 Larsucosterol 30 mg SOC p-value = 0.311 Larsucosterol 90 mg SOC
Slide 11: More Pronounced Reduction in Mortality Observed in U.S.
More Pronounced Reduction in Mortality Observed in U.S. p = 0.008 p = 0.014 -57% -58%
Slide 12: Kaplan-Meier Analysis of Mortality (U.S. Patients)
Kaplan-Meier Analysis of Mortality (U.S. Patients) p-value = 0.012 Larsucosterol 30 mg SOC p-value = 0.052 Larsucosterol 90 mg SOC
Slide 13: Larsucosterol Was Well-Tolerated
Larsucosterol Was Well-Tolerated TEAEs = Treatment Emergent Adverse Events Numerically fewer TEAEs in both 30 mg and 90 mg arms compared with SOC No meaningful difference in serious AEs and none attributed to larsucosterol p = 0.052 p = 0.190 -22% -24%
Slide 14: Conclusions and Next Steps for Larsucosterol in AH
Conclusions and Next Steps for Larsucosterol in AH Compelling efficacy signal in favor of larsucosterol in key secondary endpoint of reduced mortality at 90 days; 41% for the 30 mg dose and 35% for the 90 mg dose compared with SOC In U.S. patients, larsucosterol treatment reduced mortality at 90 day
Slide 15: Q&A
Q&A re) durect